Literature DB >> 36201386

A Data-Driven Reference Standard for Adverse Drug Reaction (RS-ADR) Signal Assessment: Development and Validation.

Suehyun Lee1, Jeong Hoon Lee2, Grace Juyun Kim2, Jong-Yeup Kim3, Hyunah Shin3, Inseok Ko3, Seon Choe2, Ju Han Kim2.   

Abstract

BACKGROUND: Pharmacovigilance using real-world data (RWD), such as multicenter electronic health records (EHRs), yields massively parallel adverse drug reaction (ADR) signals. However, proper validation of computationally detected ADR signals is not possible due to the lack of a reference standard for positive and negative associations.
OBJECTIVE: This study aimed to develop a reference standard for ADR (RS-ADR) to streamline the systematic detection, assessment, and understanding of almost all drug-ADR associations suggested by RWD analyses.
METHODS: We integrated well-known reference sets for drug-ADR pairs, including Side Effect Resource, Observational Medical Outcomes Partnership, and EU-ADR. We created a pharmacovigilance dictionary using controlled vocabularies and systematically annotated EHR data. Drug-ADR associations computed from MetaLAB and MetaNurse analyses of multicenter EHRs and extracted from the Food and Drug Administration Adverse Event Reporting System were integrated as "empirically determined" positive and negative reference sets by means of cross-validation between institutions.
RESULTS: The RS-ADR consisted of 1344 drugs, 4485 ADRs, and 6,027,840 drug-ADR pairs with positive and negative consensus votes as pharmacovigilance reference sets. After the curation of the initial version of RS-ADR, novel ADR signals such as "famotidine-hepatic function abnormal" were detected and reasonably validated by RS-ADR. Although the validation of the entire reference standard is challenging, especially with this initial version, the reference standard will improve as more RWD participate in the consensus voting with advanced pharmacovigilance dictionaries and analytic algorithms. One can check if a drug-ADR pair has been reported by our web-based search interface for RS-ADRs.
CONCLUSIONS: RS-ADRs enriched with the pharmacovigilance dictionary, ADR knowledge, and real-world evidence from EHRs may streamline the systematic detection, evaluation, and causality assessment of computationally detected ADR signals. ©Suehyun Lee, Jeong Hoon Lee, Grace Juyun Kim, Jong-Yeup Kim, Hyunah Shin, Inseok Ko, Seon Choe, Ju Han Kim. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 06.10.2022.

Entities:  

Keywords:  ADR; PV; RWD; RWE; adverse drug reaction; drug reaction; pharmacology; pharmacovigilance; real-world data; real-world evidence; reference standard

Mesh:

Substances:

Year:  2022        PMID: 36201386      PMCID: PMC9585444          DOI: 10.2196/35464

Source DB:  PubMed          Journal:  J Med Internet Res        ISSN: 1438-8871            Impact factor:   7.076


  35 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

2.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

3.  Accuracy of an automated knowledge base for identifying drug adverse reactions.

Authors:  E A Voss; R D Boyce; P B Ryan; J van der Lei; P R Rijnbeek; M J Schuemie
Journal:  J Biomed Inform       Date:  2016-12-16       Impact factor: 6.317

4.  Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance.

Authors:  Suehyun Lee; Jongsoo Han; Rae Woong Park; Grace Juyun Kim; John Hoon Rim; Jooyoung Cho; Kye Hwa Lee; Jisan Lee; Sujeong Kim; Ju Han Kim
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

5.  Research and Reporting Considerations for Observational Studies Using Electronic Health Record Data.

Authors:  Alison Callahan; Nigam H Shah; Jonathan H Chen
Journal:  Ann Intern Med       Date:  2020-06-02       Impact factor: 25.391

Review 6.  Detecting adverse events for patient safety research: a review of current methodologies.

Authors:  Harvey J Murff; Vimla L Patel; George Hripcsak; David W Bates
Journal:  J Biomed Inform       Date:  2003 Feb-Apr       Impact factor: 6.317

Review 7.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

8.  Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.

Authors:  Richard D Boyce; Patrick B Ryan; G Niklas Norén; Martijn J Schuemie; Christian Reich; Jon Duke; Nicholas P Tatonetti; Gianluca Trifirò; Rave Harpaz; J Marc Overhage; Abraham G Hartzema; Mark Khayter; Erica A Voss; Christophe G Lambert; Vojtech Huser; Michel Dumontier
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

9.  A time-indexed reference standard of adverse drug reactions.

Authors:  Rave Harpaz; David Odgers; Greg Gaskin; William DuMouchel; Rainer Winnenburg; Olivier Bodenreider; Anna Ripple; Ana Szarfman; Alfred Sorbello; Eric Horvitz; Ryen W White; Nigam H Shah
Journal:  Sci Data       Date:  2014-11-11       Impact factor: 6.444

10.  Hepatotoxicity induced by clozapine: a case report and review of literature.

Authors:  Ana Isabel Wu Chou; Mong-Liang Lu; Winston W Shen
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-26       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.